CHAARTED 试验中转移性激素敏感性前列腺癌总生存期的替代终点
该研究基于 CHAARTED 试验数据,评估转移性激素敏感性前列腺癌患者中 PSA 反应、进展及去势抵抗性前列腺癌(CRPC)发展在 6 和 12 个月内作为总生存期(OS)替代终点的可行性。共纳入 790 例患者,4 个中间临床终点符合 Prentice 替代标准,其中联合治疗后 6 个月内进展对 OS 的替代效果最佳。
要点
- 6 个月内进展是转移性激素敏感性前列腺癌 OS 的最佳替代终点。
- 6 个月和 12 个月内进展及 CRPC 发展均符合替代标准。
- 6 个月内进展者 2 年 OS 率 42%,未快速进展者为 89%。
核心结论
- 联合治疗后 6 个月内进展成为总生存期的最佳替代终点。
研究设计与样本
- 分析 CHAARTED 随机试验数据,患者随机接受雄激素剥夺治疗(ADT)或 ADT 联合多西他赛,共纳入 790 例患者。
主要发现
- 6 个月内进展的 HR 为 5.70(95%CI:4.26-7.64,p<0.001),12 个月内进展的 HR 为 7.09(95%CI:5.16-9.76,p<0.001)。
- 6 个月内发生 CRPC 的 HR 为 5.11(95%CI:3.81-6.85,p<0.001),12 个月内发生 CRPC 的 HR 为 6.24(95%CI:4.58-8.51,p<0.001)。
- 四个替代终点的治疗效应比例(PTE)分别为 88%、52%、80% 和 46%。
- 随机化后 6 个月内进展患者的 2 年 OS 率为 42%,未快速进展患者为 89%。
关键数值与推荐
- PSA 反应、进展和 CRPC 发展在 6 和 12 个月内按 Prentice 标准评估替代性。
临床怎么用
- 可将 6 个月内进展作为转移性激素敏感性前列腺癌临床试验中 OS 的替代终点,用于早期疗效评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastasis-free survival has been shown to be a robust surrogate for overall survival (OS) in men with nonmetastatic prostate cancer (PC). However, this surrogate only holds true for a select subset of patients, and leaves those trials analyzing metastatic disease at a disadvantage. We aimed to identify the best surrogate for predicting OS in patients with metastatic hormone-sensitive PC. METHODS: We analyzed data from the Chemohormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease trial in which patients were randomly assigned to receive either androgen deprivation therapy (ADT) or ADT plus docetaxel. PSA response, progression and development of castration-resistant PC (CRPC) within 6 and 12 months were investigated as potential OS surrogates, in accordance with the Prentice Criteria. The proportion the of treatment effect (PTE) was calculated for each surrogate and used to identify the best one. RESULTS: Data from 790 patients were considered: 393 (49.7%) men received ADT alone, while 397 (50.3%) received combination therapy. Four intermediate clinical endpoints met the criteria for surrogacy: progression within 6 months (HR: 5.70; 95%CI: 4.26, 7.64; p < 0.001) and 12 months (HR: 7.09; 95%CI: 5.16, 9.76; p < 0.001) as well as development of CRPC within 6 (HR: 5.11; 95%CI: 3.81, 6.85; p < 0.001) and 12 months (HR: 6.24; 95%CI: 4.58, 8.51; p < 0.001). The PTE for the four surrogates were 88%, 52%, 80%, and 46%, respectively. The 2-year OS rates for patients who progressed within 6 months of randomization were 42 versus 89% for the patient population that did not progress that quickly. CONCLUSIONS: Progression within 6 months following combination therapy emerged as the best surrogate for OS.
引用
- Martini A, Pfail J, Montorsi F, et al. Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. Prostate Cancer Prostatic Dis. 2020. PMID: 32313142. doi:10.1038/s41391-020-0231-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。